Bumetanide
A potent loop diuretic used to remove excess fluid in conditions such as heart failure, liver cirrhosis, and kidney disease. It works in the loop of Henle in the kidney to block sodium and chloride reabsorption, significantly increasing urine output. It is substantially more potent than furosemide on a milligram basis.
Molekularmasse
364,4000 g/mol
LogP
2,80
TPSA
127,00 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Wirkmechanismus
Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1
InChI
InChI=1S/C17H20N2O5S/c1-2-3-9-19-14-10-12(17(20)21)11-15(25(18,22)23)16(14)24-13-7-5-4-6-8-13/h4-8,10-11,19H,2-3,9H2,1H3,(H,20,21)(H2,18,22,23)
Molecular Formula
C17H20N2O5S
HBD / HBA
3 / 7
Rotierbare Bindungen
8
Schwere Atome
25
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
A potent loop diuretic used to remove excess fluid in conditions such as heart failure, liver cirrhosis, and kidney disease. It works in the loop of Henle in the kidney to block sodium and chloride reabsorption, significantly increasing urine output. It is substantially more potent than furosemide on a milligram basis.
Inhibits sodium reabsorption in the renal tubules, promoting excretion of sodium, chloride, and water. This reduces extracellular fluid volume and cardiac preload, lowering blood pressure.
Yes, Bumetanide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1072. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 2471. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="bumetanide"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/bumetanide/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/bumetanide/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/bumetanide/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="bumetanide"></drugfyi-drug>